BOUTIQUE精品展示
Serum-free for sensitive cell lines, like ES and primary cells, Gradual or programmable freezing is no longer necessary
BAMBANKER產(chǎn)品特點(diǎn)
即用型細(xì)胞凍存液,無需程序性降溫
尤其適用于各類敏感細(xì)胞,如ES細(xì)胞、原代細(xì)胞
高復(fù)蘇率(請(qǐng)見對(duì)比圖效果)
可-80℃或液氮中長(zhǎng)期凍存,穩(wěn)定保存1年以上
無血清,成份確定,避免由支原體、病毒、朊病毒及其他病毒顆粒引發(fā)的污染
產(chǎn)品經(jīng)無菌檢測(cè),符合日本藥典
產(chǎn)品可2~8 ℃穩(wěn)定保存2年
BAMBANKER操作流程使用說明:
收集對(duì)數(shù)生長(zhǎng)期的細(xì)胞(5 x 105 ~ 1 x 107)
用1ml BambankerTM重懸細(xì)胞,置于凍存管中,無需預(yù)冷。
品名 |
貨號(hào) |
規(guī)格 |
BambankerTM |
BB01 |
120ml |
BAMBANKER系列凍存液:
品名 |
描述 |
貨號(hào) |
規(guī)格 |
BambankerTM Direct |
細(xì)胞凍存時(shí)無需離心,非常適用于雜交瘤細(xì)胞 |
BBD01 |
20ml |
BambankerTM HRM |
使用人血清白蛋白,無動(dòng)物源性 |
BBH01 |
20ml |
BAMBANKER is manufactured by LYMPHOTEC Inc.
BAMBANKER與其他相關(guān)產(chǎn)品的復(fù)蘇率效果比較
Bambanker使用發(fā)表文獻(xiàn)(部分)
ü T. Hikichi et al., Differentiation potential of parthenogenetic embryonic stem cells is improved by nuclear transfer. Stem cells25, 46 (Jan, 2007).
ü S. Mieno et al., Characteristics and function of cryopreserved bone marrow-derived endothelial progenitor cells. The Annals of thoracic surgery85, 1361 (Apr, 2008).
ü S. Hatoya et al., Effect of co-culturing with embryonic fibroblasts on IVM, IVF and IVC of canine oocytes. Theriogenology66, 1083 (Sep 15, 2006).
ü D. Liu et al., Relation between human decay-accelerating factor (hDAF) expression in pig cells andinhibition of human serum anti-pig cytotoxicity: value of highly expressed hDAF for xenotransplantation. Xenotransplantation14, 67 (Jan, 2007).
ü S. K. Zaidi et al., Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proceedings of the National Academy of Sciences of the United States of America104, 19861 (Dec 11, 2007).
ü S. Mieno et al., Effects of diabetes mellitus on VEGF-induced proliferation response in bone marrow derived endothelial progenitor cells. Journal of cardiac surgery25, 618 (Sep, 2010).
ü Y. Shimizu et al., Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer science100, 481 (Mar, 2009).